

IMPROVEMENTS IN DRUG DELIVERY DEVICES

707  
AI

5 This invention relates to improvements in drug delivery devices and particularly those for dispensing a metered dose of medicament.

10 In metered dose inhalers, an aerosol stream from a pressurised dispensing container is fired towards a patient or user of the inhaler into an air flow. The air flow is created by a user inhaling through a mouthpiece of the inhaler and the medicament is released into this air flow at a point between the air inlet holes and the mouthpiece.

15 Conventional metering valves for use with pressurised dispensing containers comprise a valve stem co-axially slidable within a valve member defining an annular metering chamber, and outer and inner annular seals operative between the respective outer and inner ends of the valve stem and the valve member to seal the metering chamber therebetween. The  
20 valve stem is hollow whereby in a non-dispensing position of the valve stem, the metering chamber is connected to the container and charged with product therefrom. The valve stem is movable against the action of a spring to a dispensing position wherein  
25 the metering chamber is isolated from the container and vented to atmosphere for the discharge of product.

Other drug delivery devices include apparatus in which capsules containing a powdered medicament are mechanically opened at a dispensing station where  
30 inhaled air subsequently entrains the powder, which is then dispensed through a mouthpiece.

35 A problem with all such drug delivery devices is that deposition of the medicament, or a solid component from a suspension of a particulate product in a liquid propellant, on the internal surfaces and other components of the devices occurs after a number of operation cycles and/or storage. This can lead to

10047395-01702

reduced efficiency of operation of the device and of the resulting treatment in that deposition of the product reduces the amount of active drug available to be dispensed.

5           Some prior art devices rely on the dispenser being shaken in an attempt to dislodge the deposited particles as a result of the movement of a liquid propellant and product mixture. However, whilst this remedy is effective within the body of the container  
10           itself, it is not effective for particles deposited on the inner surfaces of the metering chamber. As the size of the chamber is significantly smaller, the restricted flow of fluid in the metering chamber (caused by the tortuosity of the flow path through the  
15           chamber) means that the fluid in the metering chamber does not move with enough energy to adequately remove the deposited particles.

20           One solution is proposed in our pending application GB 97211684.0 in which a liner of a material such as fluoropolymer, ceramic or glass is included to line a portion of the wall of a metering chamber in a metering valve. Although this solves the problem of deposition in these types of dispensers, it does require the re-design or modification of moldings  
25           and mould tools for producing the valve members to allow for the insertion of the liner.

30           It is an object of the present invention to provide drug delivery devices in general in which the deposition of the product and active drug component is minimised.

35           According to the invention there is provided apparatus for dispensing a medicament, wherein at least a portion of one or more of the internal surfaces of components of the apparatus which come into contact with medicament during storage or dispensing has a layer of one or more cold plasma polymerised monomers bonded to at least a portion

*insert*

*inserted  
Cont.*

thereof, with the proviso that the layer is not of a cold plasma polymerised fluorinated hydrocarbon where the apparatus is a pressurised dispensing container.

5 A particular embodiment of the present invention will now be described, by way of example only, with reference to the accompanying drawings, in which:

10 Figure 1 is a cross-sectional view through an inhaler, which is one type of drug delivery device of the present invention; and

Figure 2 is a cross-sectional view of a metering valve used in another type of drug delivery device.

15 In Figure 1, an inhaler 10 for a product such as a medicament comprises a housing 11 for receiving a pressurised dispensing container 12 of a medicament and a mouthpiece 14 for insertion into the mouth of a user of the inhaler 10.

20 The container housing 11 is generally cylindrical and open at its upper end. A lower wall 15 of the housing 11 includes an annular socket 16 for receiving the tubular valve stem 17 of the container 12. The socket 16 communicates via a duct 18 ending in an orifice 19 with the mouthpiece 14. The lower wall 15  
25 also has holes 20 for allowing air to flow through the container housing 11 into the mouthpiece 14.

The mouthpiece 14 may be generally circular or shaped to fit the mouth and is connected to or forms a part of the housing 11.

30 In use, a patient or user holds the inhaler 10, usually in one hand, and applies his mouth to the mouthpiece 14. The user then inhales through the mouthpiece 14 and this creates an air flow through the cylindrical housing 11, from its open end around the dispensing container 12, through the holes 20 and into  
35 the mouthpiece 14. After the user has started inhaling through the mouthpiece 14, the container 12

202470-93624001

is depressed downwardly onto its stem 17 to release a dose of medicament from the container 12. The dose of medicament is projected by the pressure in the container 12 via the duct 18 and through the orifice 19. It then mixes with the air flow through the mouthpiece 14 and is hence inhaled by the user.

In traditional inhalers, all of the components are plastic mouldings, which gives rise to the deposition problems described above. The particular problem areas in devices such as inhalers are the internal surfaces 21 of the mouthpiece 14, the internal surfaces 22 of the duct 18 and the walls 23 defining the orifice 19. In some inhalers 10, the diameter of at least a part of the duct 18 can be as little as 0.5mm and so any deposition on its internal surfaces 22 could lead to not only the problem of a reduction in active drug components being available, but also dispensing difficulties.

The metering valve 110 illustrated in Figure 2 is another type of drug delivery device or dispenser, and includes a valve stem 111 which protrudes from and is axially slidable within a valve member 112, the valve member 112 and valve stem 111 defining therebetween an annular metering chamber 113. The valve member 112 is located within a valve body 114 which is positioned in a pressurised container (not shown) containing a product to be dispensed. The metering valve 110 is held in position with respect to the container by means of a ferrule 115 crimped to the top of the container and sealing being provided between the valve body 114 and container by an annular gasket 116.

An outer seal 117 and an inner seal 118 of an elastomeric material extend radially between the valve stem 111 and the valve member 112. The outer seal 117 is radially compressed between the valve member 112 and valve stem 111 so as to provide positive sealing contact, the compression being achieved by using a

10047986-011702

seal which provides an interference fit on the valve stem 111 and/or by the crimping of the ferrule 115 onto the pressurised container during assembly.

5 The valve stem 111 has an end 119 which protrudes from the valve member 112 and ferrule 115 which is a hollow tube and which is closed off by flange 120 which is located within the metering chamber 113. The hollow end 119 of valve stem 111 includes a discharge port 121 extending radially through the side wall of  
10 the valve stem 111. The valve stem 111 further has an intermediate section 122, which is also hollow and defining a central passage and which has a pair of spaced radial ports 123, 124 which are interconnected through a central cavity.

15 A spring 125 extends between a second flange 126, separating the intermediate section 122 of the valve stem 111 and an inner end 127 of the valve stem 111, and an end of the valve body 114 to bias the valve stem 111 in a non-dispensing position in which the  
20 first flange 120 is held in sealing contact with the outer seal 117. The second flange 126 is located outside the valve member 112, but within the valve body 114.

25 The metering chamber 113 is sealed from the atmosphere by the outer seal 117, and from the pressurised container to which the valve 110 is attached by the inner seal 118. In the illustration of the valve 110 shown in Figure 1 radial ports 123, 124, together with the central cavity in the  
30 intermediate section 122 of the valve member 111 connect the metering chamber 113 with the container so that in this non-dispensing condition the metering member 113 will be charged with product to be dispensed.

35 Upon depression of the valve stem 111 relative to the valve member 112 so that it moves inwardly into the container, the radial port 124 is closed off as it

202110-55621001

*insert*  
*cr*

*inventor's  
conf.*

5

passes through the inner seal 118, thereby isolating the metering chamber 113 from the contents of the pressurised container. Upon further movement of the valve stem 111 in the same direction to a dispensing position the discharge port 121 passes through the outer seal 117 into communication with the metering chamber 113. In this dispensing position the product in the metering chamber 113 is free to be discharged to the atmosphere via the discharge port 121 and the cavity in the hollow end 119 of the valve stem 111.

10

When the valve stem 111 is released, the biasing of the return spring 125 causes the valve stem 111 to return to its original position. As a result the metering chamber 113 becomes re-charged in readiness for further dispensing operations.

15

The component parts of conventional drug dispensing devices, such as valve members, valve stems, inhaler housings and so on, are generally formed as single mouldings from material such as acetal, polyester or nylon which are prone to the deposition problems described above. Although in some cases it might be possible to include a separate liner of a material such as a fluoropolymer, ceramic or glass to line a portion of the area in which deposition problems occurs, this requires the re-design or modification of mouldings and mould tools so that the components can accommodate such liners.

20

25

In the present invention we propose a solution in which the component parts of the drug dispensing devices are made by conventional tooling and moulds from the traditional materials listed above. They are then subjected to a cold plasma polymerisation treatment of one or more monomers which is a "hydrophobic" treatment which creates a very thin layer of the plasma polymer on the surface of the component parts which significantly reduces the deposition of active drugs on the relevant surfaces

30

35

1004986-01001

due to factors such as anti-frictional and waterproof characteristics and low surface energy.

*inserted*  
5 The preferred monomers to use in this process where the apparatus is not a pressurised dispensing container are perfluoro-cyclohexane or perfluoro-hexane which would create a thin layer of plasma polymerised fluoro-cyclohexane or fluoro-hexane on the appropriate surface. Other fluorinated hydrocarbons may also be used, such as tetrafluoroethylene (TFE),  
10 trifluoroethylene, vinylidene fluoride and vinyl fluoride. The two monomers fluoroethylene and fluoropropylene may also be used to form the co-polymer fluorinated ethylene-propylene (FEP). Siloxanes, such as dimethyl siloxane, may be used with  
15 all of the above mentioned drug dispensing devices to give a layer of plasma polymerised dimethylsiloxane.

The process is known as "cold plasma" treatment as the temperature within the body of the plasma is ambient. Thus thermoplastic materials such as  
20 polybutyrene terephthalate (PBT), nylon, acetile and tetrabutylene terephthalate (TBT) can be treated without fear of thermal damage. The treatment is a vacuum procedure in which the components are placed inside a chamber which is evacuated to less than 0.005  
25 Torr. One or more monomers are introduced to the chamber at a controlled rate and a 13.56 MHz r.f. signal is applied to an external antenna. The plasma is ignited within the chamber and maintained for a given time at the pre-selected power setting. At the  
30 end of the treatment, the plasma is extinguished, the chamber flushed and the products retrieved. As a result a thin layer (for example 0.005 to 0.5 microns) of the plasma polymerised material is intimately bonded to the surface of the component.

*inserted*  
35 Either an entire component within the drug delivery device, or just the surfaces of one or more component which would come into contact with the

10047986 04702

*inserted  
Cont.*

5 medicament during actuation, could be treated to  
provide an improved drug delivery device according to  
the present invention. In the case of the type of  
inhalers as shown in Figure 1, surfaces 21, 22 and 23  
may be treated. In a typical dry powder inhaler, the  
inner surface of the mouthpiece and any channel  
leading to the mouthpiece from the point of powder  
storage, i.e., from a capsule, bulk storage chamber or  
a pre-metered chamber of a device. In the metering  
10 valve of Figure 2, the valve member 112 alone may be  
treated. However, additional benefits can be achieved  
in treating some or all of the other plastic and  
rubber parts of the valve, including the valve body  
114 and the seals 116, 117 and 118. Treatment of the  
15 seals 117 and 118 has the additional benefit that  
friction between the seals 117 and 118 and valve stem  
111 is reduced resulting in easier operation of the  
device. The level of friction between the valve stem  
111 and seals 117 and 118 may be further reduced by  
20 treatment of the valve stem 111 itself. Such  
treatment reduces or eliminates the need for silicone  
emulsions or oils to be applied to the seals 117 and  
118 and valve stem 111. Treatment of the seals 116,  
117 and 118 also has the benefits of reducing levels  
25 of extractibles where the seals are manufactured from  
elastomeric materials, reducing the permeability of  
the seals to the propellant in the pressurised  
dispensing container and reducing the levels of  
absorption of product onto the surfaces of the seals.  
30 The method can also be used to treat components of  
many other delivery devices including nasal pumps,  
non-pressurised actuators, foil storage types, breath  
actuated inhaler devices and breath co-ordinating  
devices and so on.

35

10047986 04702  
20210 93624007